Glaxo in Trouble over Claims Against Avandia Diabetes Drug

.

Glaxo in Trouble over Claims Against Avandia Diabetes Drug

There have been claims that Avandia diabetes drug is causing high risk of heart attacks and congestive heart failure to the users. And in this regard, around four Lawsuits have been filed in the UK against the producer, GlaxoSmithKline Plc (GSK).

Avandia was once known as the world's best diabetes pill but now has been surrounded amid several claims.

Daniel Slade is the lawyer involved and he is representing consumers in four lawsuits. In addition, there are 15 more clients in his list of this case. As revealed by him, the potential number of claims against GSK seems to go higher in a short period of time.

He commented during a telephonic interview: "We expect the number of claims to increase as there are potentially thousands of people out there who took Avandia in the U. K. Hopefully these claims will lead to more careful studies and checks on drugs that are widely marketed".

To settle down the claims of marketing Avandia along with other medication in an illegal manner; Glaxo had already paid more than $3 billion to the U. S. federal and state government.

David Daley, a spokesman for Brentford, UK-based Glaxo, while sympathizing with people suffering from health complications related with diabetes said that the company is bound to comment over any such cases.

 


Latest News

1,200 Pounds of Ground Beef Recalled by Ranchers Legacy Meat Company Due to E. c
Uber Needs to Mend Ways to Correct its Image
Amazon Fire TV Stick will offer stiff competition to Neflix and Hulu Plus
New Chromebook buyers get 1TB free Google Drive storage space
China Adds Fresh Stimulus to Pep Up Growth
End of Harvest Season Results in Job Losses in Farming Sector
WalletHub Released a List of Best Deals on Black Friday
Massachusetts Regulators to Decide on Issue of Limiting time and Money for Gambl
More People Are Expected to Travel by Road during the Thanksgiving Holiday, due
Sotheby’s CEO, William Ruprecht to Step Down
Alibaba does well in the American Bond Market
Target's Holiday Season Sales Expected to Fetch Good Results